Trevena stock soars toward 5-fold gain in very active trading, after pain treatment gets approved in China

Shares of Trevena Inc. (TRVN) exploded more than five-fold higher -- up 420.6% -- on very active trading Monday, after the Pennsylvania-based biopharmaceutical company said its China-based partner Jiangsu Nhwa received formal approval from China health regulators for the pain treatment Olinvyk. The stock, which had been halted 21 times for volatility since the open, has seen 75.7 million shares change hands, compared with the full-day average over the past 30 days of about 111,100 shares. Trevena said Olinvyk, which was approved by the U.S. Food and Drug Administration in August 2020, has been approved by China's National Medical Products Administration (NMPA) for use in adults to treat acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. Trevena is in line to receive a $3 million milestone payment from Jiangsu Nhwa, and is also eligible to receive $15 million upon the first commercial sales of Olinvyk in China. Trevena's stock has now rallied 129.4% year to date, while the iShares Biotechnology exchange-traded fund (IBB) has slipped 0.5% and the S&P 500 has gained 7.7%.

-Tomi Kilgore

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

05-08-23 1332ET

Copyright (c) 2023 Dow Jones & Company, Inc.